April 2022 - Volume 81 - 4

EDITORIAL

1. What evidence is needed to demonstrate the beneficial effects of exercise for osteoarthritis?

REVIEW

2. Cutaneous signs and mechanisms of inflammasomopathies (17 January, 2022)

VIEWPOINT

3. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’? (16 October, 2021)

RHEUMATOID ARTHRITIS

4. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

5. Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor

PSORIATIC ARTHRITIS

6. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis

SYSTEMIC LUPUS ERYTHEMATOSUS

7. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis  

SYSTEMIC SCLEROSIS

8. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaireEditor's Choice

9. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time

VASCULITIS

10. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis

OSTEOARTHRITIS

11. Exercise and education versus saline injections for knee osteoarthritis: a randomised controlled equivalence trial

12. Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis (1 December, 2021)

CRYSTAL ARTHROPATHIES

13. Impact of adiposity on risk of female gout among those genetically predisposed: sex-specific prospective cohort study findings over >32 years (2 December, 2021)

EPIDEMIOLOGY

14. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong

15. Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study

16. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus

17. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection

LETTERS

18. Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors

19. Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis

20. Herpes zoster reactivation after mRNA-1273 vaccination in patients with rheumatic diseases

21. Hypoglycaemia following JAK inhibitor treatment in patients with diabetes

22. Clinical characteristics of juvenile gout and treatment response to febuxostat

ELECTRONIC PAGES

23. Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a ‘mix-and-match’ approach?

24. Response to: ‘Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a ‘mix-and-match’ approach’ by Alunno et al 

25. Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis

26. Response to: ‘Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis’ by Bugatti et al 

27. Withdrawal of low-dose prednisone in inactive SLE patients: Is there another alternative?

28. Response to: ‘Withdrawal of low-dose prednisone in inactive SLE patients: is there another alternative?’ by Sabio

29. External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies

30. Response to: ‘External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies’ by Luu et al 

31. Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease

32. Response to: ‘Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease’ by Sato et al 

33. Is non-industrial society undergoing an energy balance transition predisposed to accumulate abdominal adipose tissue and susceptible to knee osteoarthritis?

34. Response to: ‘Is non-industrial society undergoing an energy balance transition predisposed to accumulate abdominal adipose tissue and susceptible to knee osteoarthritis?’ by Yu et al 

35. Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues

36. Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera

37. JAK inhibitors as promising agents for refractory Takayasu arteritis

38. Response to: ‘JAK inhibitors as promising agents for refractory Takayasu arteritis’ by Watanabe

ISSUE INFORMATION